Results 131 to 140 of about 1,034,274 (259)

Delphi consensus: First‐line use of biologics and small molecules in hidradenitis suppurativa

Journal of the European Academy of Dermatology and Venereology, EarlyView.
This Delphi Consensus study identified upgrade criteria for the use of biologics and small molecules as first‐line therapy in hidradenitis suppurativa (HS). European HS experts evaluated 16 clinical scenarios, voting on eligibility for therapy escalation.
Georgios Nikolakis, Erkan Alpsoy, Florian Anzengruber, Matthias Augustin, Falk G. Bechara, Pierre‐André Becherel, Farida Benhadou, Vincenzo Bettoli, Joana Cabete, Raffaele Dante Caposiena Caro, Antonella Di Cesare, Giovanni Damiani, Valentina Dini, Evangelos J. Giamarellos‐Bourboulis, Krisztián Gáspár, Katalin Glasenhardt, Philippe Guillem, Ariela Hafner, Barbara Horvath, John R. Ingram, Vaiva Jarienè, Gregor B. E. Jemec, Alexander Katoulis, Natalia Kirsten, Georgios Kokolakis, Piotr K. Krajewski, Aikaterini I. Liakou, Flavia Manzo Margiotta, Angelo V. Marzano, Antonio Martorell, Lukasz Matusiak, Dillon Mintoff, Alejandro Molina Leyva, Andreas Pinter, Anna Pirogova, Maurizio Podda, Francesca Prignano, Jorge Romani, Marco Romanelli, Elia Rosi, Samed Sahin, Ditte M. L. Saunte, Sylke Schneider‐Burrus, Mariano Suppa, Jacek Szepietowski, Andrea Szegedi, Simon Francis Thomsen, Thrasyvoulos Tzellos, Anastasia Trigoni, Hessel H. Van Der Zee, Kelsey Van Straalen, Skaidra Valiukevičiene, Eva Vilarrasa, Esther von Stebut, Christos C. Zouboulis   +54 more
wiley   +1 more source

Safety and pharmacokinetics of anumigilimab for hidradenitis suppurativa or palmoplantar pustulosis: A phase 1b study

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Anumigilimab, a novel anti‐G‐CSF receptor antibody, was investigated in a phase 1b trial involving 39 patients with hidradenitis suppurativa or palmoplantar pustulosis. No serious safety concerns related to anumigilimab were noted, and PK and PD were dose dependent.
Johannes S. Kern, Simon Francis Thomsen, Georgios Kokolakis, Maurizio Podda, Gregor B. E. Jemec, Kurt Gebauer, Claus Zachariae, John Frew, Pablo Fernandez‐Peñas, Falk G. Bechara, Stefan Beissert, Sourabh Malandkar, Karen Scalzo‐Inguanti, Partha Nandy, Selvakumar Sukumar   +14 more
wiley   +1 more source

Can imaging be a proxy for remission in axial spondyloarthritis?

, 2020
Targeting clinical remission is currently the focus of the treat-to-target strategy. Defining clinical outcomes as the main achievable treatment goal questions whether imaging remission should also be considered in the treat-to-target concept.
Aouad, Krystel, Carron, Philippe, De Craemer, Ann-Sophie   +2 more
core   +1 more source

European S2k guidelines for hidradenitis suppurativa/acne inversa Part 1. Epidemiology, diagnosis and clinical assessment

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Updated S2k hidradenitis suppurativa (HS) guidelines provide expert consensus on diagnosis, assessment and comorbidities. Expanded substantially since the 2015 version, they reflect rapid growth in HS literature and aim to improve generalist‐level patient care through evidence‐informed, consensus‐based guidance.
G. B. E. Jemec, B. Villumsen, K. R. van Straalen, H. H. van der Zee, S. Valiukevičienė, T. Tzellos, J. C. Szepietowski, A. Szegedi, D. M. L. Saunte, M. Romanelli, H. Raynal, F. Prignano, E. P. Prens, M. Podda, A. Nassif, A. Molina‐Leyva, Ł. Matusiak, A. V. Marzano, B. M. McGrath, A. I. Liakou, B. Kirby, L. Kemény, E. Just, D. Ioannidis, J. R. Ingram, R. E. Hunger, B. Horváth, P. Guillem, Ø. Grimstad, E. J. Giamarellos‐Bourboulis, M. Dolenc‐Voljč, V. Del Marmol, Z. Bukvić Mokos, V. Bettoli, F. Benhadou, F. G. Bechara, C. C. Zouboulis   +36 more
wiley   +1 more source

Autoimmunity and Periodontitis

Journal of Periodontal Research, EarlyView.
In a microbe‐driven inflammatory environment, peptidyl‐arginine deiminase (PAD) enzymes from neutrophils and Porphyromonas gingivalis citrullinate both microbial and self‐antigens. B cell presentation of citrullinated or self‐mimicking epitopes activates T cells that assist B cells in antibody isotype switching, affinity maturation, epitope spreading ...
Massimo Costalonga, Vivek Thumbigere‐Math, Mark C. Herzberg   +2 more
wiley   +1 more source

Mucosal‐Associated Invariant T Cells in Health and Disease

MedComm, Volume 7, Issue 10, October 2026.
The roles of MAIT cells in health and disease and their therapeutic applications. In healthy individuals, riboflavin metabolites secreted by commensal bacteria at mucosal sites are presented by MR1, leading to the activation of MAIT cells. Activated MAIT cells can maintain the barrier integrity of mucosal tissues in a steady state or migrate to the ...
Yu Zhao, Feng‐Mi Ou, Dan Liang, Yang Gao, Qing‐Qing Li, Yi‐Qun Kuang   +5 more
wiley   +1 more source

Vascularized joint‐on‐a‐chip: A paradigm shift for arthritis pathophysiology and clinical treatment

Rheumatology &Autoimmunity, EarlyView.
Danli Cui, Yichi Zhang, Linkai Jiang, Haoyue Luo, Wei Huang, Zhong Alan Li, Yiting Lei   +6 more
wiley   +1 more source

Reduction of CXCR3+CCR6+ CD4+ T Cells and IL‐17+ RORγt+ CD4+ T Cells During Secukinumab Treatment Identifies Patients With Axial Spondyloarthritis Responsive to Subsequent Biologic Therapy

ACR Open Rheumatology, Volume 8, Issue 9, September 2026.
Objective We recently reported an immune profile that stratifies patients with axial spondyloarthritis based on clinical response to secukinumab. We now undertake an exploratory study on the secukinumab nonresponder patients to determine if immunologic changes occur during their initial secukinumab treatment that could determine their next biologic ...
Addison Pacheco, Patricia Remalante‐Rayco, Nigil Haroon, Denis Poddubnyy, Robert D. Inman   +4 more
wiley   +1 more source

Active axial spondyloarthritis: potential role of certolizumab pegol

, 2014
Sriya Ranatunga, Anne V Miller Department of Internal Medicine, Southern Illinois University School of Medicine, Springfield, IL, USA Abstract: The axial spondyloarthropathies are a group of chronic inflammatory diseases that predominantly affect the ...
Miller AV, Ranatunga S
core  

Current Challenges in Managing SpA

Journal of Clinical Rheumatology and Immunology
Managing spondyloarthritis (SpA) presents several complex challenges that impact patient outcomes. One of the foremost issues is the delay in diagnosis, often due to overlapping symptoms with other conditions and insufficient awareness among clinicians ...
Georg Schett
doaj   +1 more source